Sunshine Biopharma (SBFM)

$1.40 0.00 (N/A)
Market Cap 6.38M
Revenue (ttm) 34.87M
Net Income (ttm) -5.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -14.71%
Debt to Equity Ratio 0.00
Volume 45,500
Avg Vol 122,072
Day's Range N/A - N/A
Shares Out 4.56M
Stochastic %K 22%
Beta 1.45
Analysts Strong Sell
Price Target $7.00

Company Profile

Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pa...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: (954) 330-0684
Address:
333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, United States
Pomacanthus
Pomacanthus Aug. 7 at 5:42 PM
$SBFM $15 SP just around the corner going on 3 yrs now…
0 · Reply
Ejannsen
Ejannsen Aug. 7 at 3:57 PM
$SBFM
0 · Reply
MxPw
MxPw Aug. 7 at 1:15 AM
$SBFM all the bullish folks in here are just luring more of you to the slaughter , they are the ones selling on you and trapping you then blame it on the bearish folks that warned you. literally every shit co and penny stock squeezed and ran the market keeps making new highs and this ... ya see you next eventual reverse split, hope yall get a pump to $3-10 before that on the final euphoric pump that will come but remember to sell if you get it
1 · Reply
contra7
contra7 Aug. 6 at 7:50 PM
$SBFM This company has launched at least 1 new generic drug in every month since last August except October and February. In 4 out of 10 of those months they launched multiple generics. With 12 more generics due before end of year we should see a new launch PR very soon. Hopefully we see a significant partnership or distribution deal as well. Some Form 4 filings disclosing insider buying would be nice too, company officers have very little skin in the game at the moment.
1 · Reply
stockanalyzer777
stockanalyzer777 Aug. 6 at 7:13 PM
$SBFM Still bullish on this stock. ER is scheduled for 08/14/2025. Cant wait for an upward trend. Wont sell until I see >$10.00.
1 · Reply
Love_To_Learn
Love_To_Learn Aug. 6 at 11:15 AM
$SBFM have placed volume absorbers on your grid for a while now 17% intensity will lower it a bit the absorbers
0 · Reply
Planetpaprika
Planetpaprika Aug. 5 at 8:20 PM
$SBFM this amendment (!) now mandates that all outstanding Series B Warrants may only be exercised for cash, eliminating any prior provisions for cashless (net share settlement) exercises. They updated the exercise price, current exercise price has been adjusted from $2.7879 to $2.07 per warrant. And increased the number of warrants+shares (Series B Warrants has grown from approx. 12.93 million to 15,577,965 shares, now covered by the offering).
1 · Reply
Planetpaprika
Planetpaprika Aug. 5 at 5:24 PM
$SBFM Sunshine Biopharma Inc. is offering 15,577,965 shares of common stock. The shares are issuable upon exercise of outstanding Series B Warrants which were issued in our public offering that closed on February 15, 2024, have a current exercise price of $2.07, and expire February 15, 2029. The number of shares underlying the Series B Warrants and exercise price are subject to further adjustment. https://sunshinebiopharma.com/sec-filings/
1 · Reply
BullDurham22
BullDurham22 Aug. 5 at 3:49 PM
$SBFM I've been here for less than 6 months and down about 45%. This doesn’t look like a great move
1 · Reply
Ak2717
Ak2717 Aug. 1 at 10:56 PM
$IXHL Read and make your Dd. Case Studies – When Algos Lost Control 1. $COSM (Dec 2022) • Before breakout: • Barcoding for 4 days under $0.25 • 90%+ dark pool volume • No retail momentum • Trigger: • Reverse split announced + huge retail campaign • Volume jumped 20x average • Algos flipped LONG, price exploded 500%+ in 2 days 🧠 Lesson: Catalyst + volume > algos. 2. $GNS (Jan 2023) • Before breakout • Accumulation under $1.10 • FTDs & naked shorting allegations • Algo-controlled tight range • Trigger • CEO announced action against naked shorts • Media attention + Twitter campaign • Volume 30x normal → stock flew to $5+ 🧠 Lesson: Public pressure + media spotlight = algo break 3. $SBFM (May 2023) • Before breakout • VWAP pinned for 7 straight sessions • Retail frustration, low volume • Trigger: • High borrow cost spike + unexpected PR • Algos caught off guard • Price went from $0.08 → $0.34 intraday (4x) 🧠 Lesson: Low float + high borrow rate = squeeze setup
0 · Reply
Latest News on SBFM
Sunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics Market

Jul 2, 2025, 8:00 AM EDT - 5 weeks ago

Sunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics Market

Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market

Jun 11, 2025, 8:30 AM EDT - 2 months ago

Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market

Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year

May 15, 2025, 4:15 PM EDT - 3 months ago

Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year

Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market

May 6, 2025, 8:30 AM EDT - 3 months ago

Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market

Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion

Apr 21, 2025, 8:30 AM EDT - 3 months ago

Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion

Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering

Apr 3, 2025, 10:50 AM EDT - 4 months ago

Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering

Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

Apr 2, 2025, 1:20 PM EDT - 4 months ago

Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug

Apr 2, 2025, 11:35 AM EDT - 4 months ago

Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug

Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer

Apr 2, 2025, 8:00 AM EDT - 4 months ago

Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer

Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year

Apr 1, 2025, 5:09 PM EDT - 4 months ago

Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year

Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada

Mar 24, 2025, 8:00 AM EDT - 4 months ago

Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada

Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market

Mar 10, 2025, 9:00 AM EDT - 5 months ago

Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market

Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT

Jan 21, 2025, 8:00 AM EST - 7 months ago

Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT

Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer

Jan 15, 2025, 8:00 AM EST - 7 months ago

Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer

Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus

Dec 9, 2024, 7:30 AM EST - 8 months ago

Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus

Sunshine Biopharma Launches a New Generic Prescription Drug

Dec 4, 2024, 4:05 PM EST - 8 months ago

Sunshine Biopharma Launches a New Generic Prescription Drug

Sunshine Biopharma Announces Breakthrough Research Results on the Company's K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma

Dec 2, 2024, 8:00 AM EST - 8 months ago

Sunshine Biopharma Announces Breakthrough Research Results on the Company's K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma

Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%

Nov 6, 2024, 8:00 AM EST - 9 months ago

Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%

Sunshine Biopharma Launches Two New Generic Prescription Drugs

Sep 26, 2024, 8:00 AM EDT - 11 months ago

Sunshine Biopharma Launches Two New Generic Prescription Drugs

Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry

Sunshine Biopharma Has Launched Nine New Generic Prescription Drugs in 2024: Now Marketing Sixty-One Generic Drugs in Canada

Aug 26, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Has Launched Nine New Generic Prescription Drugs in 2024: Now Marketing Sixty-One Generic Drugs in Canada

Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61%

Aug 19, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61%

Sunshine Biopharma Announces Reverse Stock Split

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Announces Reverse Stock Split

Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)

Apr 19, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)

Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023

Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering

Feb 15, 2024, 9:15 AM EST - 1 year ago

Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering

Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering

Feb 13, 2024, 9:00 AM EST - 1 year ago

Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering

Sunshine Biopharma Moves Principal Office to New York City

Dec 4, 2023, 8:30 AM EST - 1 year ago

Sunshine Biopharma Moves Principal Office to New York City

Sunshine Biopharma Reports 2023 Third Quarter Results: Revenues up Significantly Over Last Year Due to a Key Acquisition

Nov 13, 2023, 8:30 AM EST - 1 year ago

Sunshine Biopharma Reports 2023 Third Quarter Results: Revenues up Significantly Over Last Year Due to a Key Acquisition

Sunshine Biopharma Receives 180-Day Extension To Achieve Nasdaq Minimum Bid Compliance

Sep 21, 2023, 9:05 PM EDT - 2 years ago

Sunshine Biopharma Receives 180-Day Extension To Achieve Nasdaq Minimum Bid Compliance

Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%

Aug 11, 2023, 8:30 AM EDT - 2 years ago

Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $5.0 Million Private Placement Priced At-the-Market for Sunshine Biopharma, Inc. (NASDAQ:SBFM)

May 16, 2023, 2:15 PM EDT - 2 years ago

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $5.0 Million Private Placement Priced At-the-Market for Sunshine Biopharma, Inc. (NASDAQ:SBFM)

Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-Market

May 16, 2023, 9:58 AM EDT - 2 years ago

Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-Market

Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market

May 12, 2023, 8:00 AM EDT - 2 years ago

Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market

Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%

May 11, 2023, 9:00 AM EDT - 2 years ago

Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%

Sunshine Biopharma Reports Full Year Ended December 31, 2022 Financial Results and Provides Corporate Update

Apr 5, 2023, 8:00 AM EDT - 2 years ago

Sunshine Biopharma Reports Full Year Ended December 31, 2022 Financial Results and Provides Corporate Update

Sunshine Biopharma Signs Exclusive Worldwide License With University of Arizona For PLpro-Based Covid-19 Treatment

Feb 28, 2023, 7:30 AM EST - 2 years ago

Sunshine Biopharma Signs Exclusive Worldwide License With University of Arizona For PLpro-Based Covid-19 Treatment

Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound

Feb 10, 2023, 7:35 AM EST - 2 years ago

Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound

Sunshine Biopharma Announces Share Repurchase Program

Jan 19, 2023, 7:30 AM EST - 2 years ago

Sunshine Biopharma Announces Share Repurchase Program

Sunshine Biopharma's Annual Letter to Shareholders

Dec 20, 2022, 8:00 AM EST - 2 years ago

Sunshine Biopharma's Annual Letter to Shareholders

4 Stocks Meeting GuruFocus' Value Screens in December

Dec 5, 2022, 5:46 PM EST - 2 years ago

4 Stocks Meeting GuruFocus' Value Screens in December

RM CACC WFG

Sunshine Biopharma Enters Into a Collaboration Agreement with a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer mRNA Project

Nov 16, 2022, 8:00 AM EST - 2 years ago

Sunshine Biopharma Enters Into a Collaboration Agreement with a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer mRNA Project

Sunshine Biopharma Announces the Acquisition of Nora Pharma, Adding $10.7 Million in Revenue

Oct 20, 2022, 8:00 AM EDT - 3 years ago

Sunshine Biopharma Announces the Acquisition of Nora Pharma, Adding $10.7 Million in Revenue

Sunshine Biopharma Files Its Second Quarter Report With the SEC

Aug 4, 2022, 8:00 AM EDT - 3 years ago

Sunshine Biopharma Files Its Second Quarter Report With the SEC

Sunshine Biopharma Increases Support for Anti-Coronavirus Collaborative Research With the University of Arizona

Jul 28, 2022, 8:10 AM EDT - 3 years ago

Sunshine Biopharma Increases Support for Anti-Coronavirus Collaborative Research With the University of Arizona

Sunshine Biopharma: An Opportunity Knocking?

May 9, 2022, 11:03 AM EDT - 3 years ago

Sunshine Biopharma: An Opportunity Knocking?

Sunshine Biopharma, Inc. Announces Closing of $19.5 Million Private Placement Priced At-the-Market

Apr 28, 2022, 4:50 PM EDT - 3 years ago

Sunshine Biopharma, Inc. Announces Closing of $19.5 Million Private Placement Priced At-the-Market

Aegis Capital Corp. acted as Exclusive Placement Agent on a $19.5 Million Private Placement Priced At-the-Market for Sunshine Biopharma Inc. (NASDAQ: SBFM)

Apr 28, 2022, 9:20 AM EDT - 3 years ago

Aegis Capital Corp. acted as Exclusive Placement Agent on a $19.5 Million Private Placement Priced At-the-Market for Sunshine Biopharma Inc. (NASDAQ: SBFM)

Sunshine Biopharma, Inc. Announces Pricing of $19.5 Million Private Placement Priced At-the-Market

Apr 26, 2022, 12:41 AM EDT - 3 years ago

Sunshine Biopharma, Inc. Announces Pricing of $19.5 Million Private Placement Priced At-the-Market

Why Sunshine Biopharma Stock Is Surging

Apr 25, 2022, 10:57 AM EDT - 3 years ago

Why Sunshine Biopharma Stock Is Surging

Pomacanthus
Pomacanthus Aug. 7 at 5:42 PM
$SBFM $15 SP just around the corner going on 3 yrs now…
0 · Reply
Ejannsen
Ejannsen Aug. 7 at 3:57 PM
$SBFM
0 · Reply
MxPw
MxPw Aug. 7 at 1:15 AM
$SBFM all the bullish folks in here are just luring more of you to the slaughter , they are the ones selling on you and trapping you then blame it on the bearish folks that warned you. literally every shit co and penny stock squeezed and ran the market keeps making new highs and this ... ya see you next eventual reverse split, hope yall get a pump to $3-10 before that on the final euphoric pump that will come but remember to sell if you get it
1 · Reply
contra7
contra7 Aug. 6 at 7:50 PM
$SBFM This company has launched at least 1 new generic drug in every month since last August except October and February. In 4 out of 10 of those months they launched multiple generics. With 12 more generics due before end of year we should see a new launch PR very soon. Hopefully we see a significant partnership or distribution deal as well. Some Form 4 filings disclosing insider buying would be nice too, company officers have very little skin in the game at the moment.
1 · Reply
stockanalyzer777
stockanalyzer777 Aug. 6 at 7:13 PM
$SBFM Still bullish on this stock. ER is scheduled for 08/14/2025. Cant wait for an upward trend. Wont sell until I see >$10.00.
1 · Reply
Love_To_Learn
Love_To_Learn Aug. 6 at 11:15 AM
$SBFM have placed volume absorbers on your grid for a while now 17% intensity will lower it a bit the absorbers
0 · Reply
Planetpaprika
Planetpaprika Aug. 5 at 8:20 PM
$SBFM this amendment (!) now mandates that all outstanding Series B Warrants may only be exercised for cash, eliminating any prior provisions for cashless (net share settlement) exercises. They updated the exercise price, current exercise price has been adjusted from $2.7879 to $2.07 per warrant. And increased the number of warrants+shares (Series B Warrants has grown from approx. 12.93 million to 15,577,965 shares, now covered by the offering).
1 · Reply
Planetpaprika
Planetpaprika Aug. 5 at 5:24 PM
$SBFM Sunshine Biopharma Inc. is offering 15,577,965 shares of common stock. The shares are issuable upon exercise of outstanding Series B Warrants which were issued in our public offering that closed on February 15, 2024, have a current exercise price of $2.07, and expire February 15, 2029. The number of shares underlying the Series B Warrants and exercise price are subject to further adjustment. https://sunshinebiopharma.com/sec-filings/
1 · Reply
BullDurham22
BullDurham22 Aug. 5 at 3:49 PM
$SBFM I've been here for less than 6 months and down about 45%. This doesn’t look like a great move
1 · Reply
Ak2717
Ak2717 Aug. 1 at 10:56 PM
$IXHL Read and make your Dd. Case Studies – When Algos Lost Control 1. $COSM (Dec 2022) • Before breakout: • Barcoding for 4 days under $0.25 • 90%+ dark pool volume • No retail momentum • Trigger: • Reverse split announced + huge retail campaign • Volume jumped 20x average • Algos flipped LONG, price exploded 500%+ in 2 days 🧠 Lesson: Catalyst + volume > algos. 2. $GNS (Jan 2023) • Before breakout • Accumulation under $1.10 • FTDs & naked shorting allegations • Algo-controlled tight range • Trigger • CEO announced action against naked shorts • Media attention + Twitter campaign • Volume 30x normal → stock flew to $5+ 🧠 Lesson: Public pressure + media spotlight = algo break 3. $SBFM (May 2023) • Before breakout • VWAP pinned for 7 straight sessions • Retail frustration, low volume • Trigger: • High borrow cost spike + unexpected PR • Algos caught off guard • Price went from $0.08 → $0.34 intraday (4x) 🧠 Lesson: Low float + high borrow rate = squeeze setup
0 · Reply
Irakli2508
Irakli2508 Aug. 1 at 9:27 PM
$SBFM
1 · Reply
KevTheCPA
KevTheCPA Aug. 1 at 4:23 PM
$COSM $GNS $IXHL $SBFM
0 · Reply
Ak2717
Ak2717 Aug. 1 at 4:20 PM
$IXHL Case Studies – When Algos Lost Control 1. $COSM (Dec 2022) • Before breakout: • Barcoding for 4 days under $0.25 • 90%+ dark pool volume • No retail momentum • Trigger: • Reverse split announced + huge retail campaign • Volume jumped 20x average • Algos flipped LONG, price exploded 500%+ in 2 days 🧠 Lesson: Catalyst + volume > algos. ⸻ 2. $GNS (Jan 2023) • Before breakout: • Accumulation under $1.10 • FTDs & naked shorting allegations • Algo-controlled tight range • Trigger: • CEO announced action against naked shorts • Media attention + Twitter campaign • Volume 30x normal → stock flew to $5+ 🧠 Lesson: Public pressure + media spotlight = algo break. ⸻ 3. $SBFM (May 2023) • Before breakout: • VWAP pinned for 7 straight sessions • Retail frustration, low volume • Trigger: • High borrow cost spike + unexpected PR • Algos caught off guard • Price went from $0.08 → $0.34 intraday (4x) 🧠 Lesson: Low float + high borrow rate = squeeze setup. Option 2 👍
5 · Reply
Catracho5
Catracho5 Aug. 1 at 1:40 PM
$SBFM When is the next offering or split? 🤔
1 · Reply
LH1975New
LH1975New Aug. 1 at 8:39 AM
$SBFM Sunshine Bio recently launched Niopeg, a Neulasta biosimilar. Some industry commentary below from "First Word Pharma" industry mag: "Biologic drug sales in Canada reached $10 billion in 2020, accounting for about one-third of total pharmaceutical spending (canada.ca/). NEULASTA® is one of the key biologics used in oncology, and its biosimilars have been gaining traction, especially after provincial switching policies were introduced to encourage cost savings."
0 · Reply
Nuisance
Nuisance Jul. 31 at 4:47 PM
$SBFM 🔥Get ready, folks! The moment we've been waiting for is finally here. Sunshine Biopharma is on the verge of an explosive breakout! 🚀 After a period of consolidation, all signs are pointing towards a significant upward movement. The time for this stock to truly shine has arrived, and I believe we're about to see its market capitalization soar towards the $100 million mark.🔥
2 · Reply
Love_To_Learn
Love_To_Learn Jul. 31 at 12:35 PM
$SBFM require your assistance lil one
0 · Reply
Jimesica
Jimesica Jul. 30 at 9:33 PM
$SBFM Just a matter of time until profitability. Was hoping it would have been sooner, but still nice growth. Niopeg will deliver significant revenue, so excited to see those numbers growing every quarter!
0 · Reply
Nuisance
Nuisance Jul. 30 at 4:18 PM
$SBFM when🚀
1 · Reply
contra7
contra7 Jul. 29 at 10:16 PM
$SBFM You’d be hard pressed to find another biotech company with a market cap(7 mill) less than quarterly revenue( 9 mill expecting 11.5 Q2) and less than cash on hand( 8 mill) , that has launched 21 new prescription drugs in Canada (several with multi billion dollar global markets) since last August including their first wholly owned bio similar NIOPEG with 12 more generics to be launched this year, over 150 times revenue growth since 2021 and last years revenue( 34.8 mill ) showing 45% year over year growth, positive oncology pipeline results, multiple new hires to facilitate rapid expansion and imminent entry into the ripe US generic market via Florida the first state to allow imported generics and the new home of the company’s headquarters. With all these positive developments the SP is down over 75% since last August and not far from all time lows (1.17). Apparently there are some over leveraged shorts here as well to make it even more interesting…only a matter of time.
1 · Reply
Irakli2508
Irakli2508 Jul. 29 at 10:00 PM
$SBFM
0 · Reply
contra7
contra7 Jul. 28 at 7:58 PM
$SBFM Short interest shares just went from 89,600 back up to 305,900. Dark pool volume remains extremely high @ 85%.
1 · Reply